Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSureĀ® Predict Prognostic Test for Alzheimer's Disease
MILAN, Nov. 21, 2022 /PRNewswire/ -- Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced key additions to its senior management team. Sam Agus, MD, has been appointed Chief Medical Officer (CMO), James Clarke, PhD, has been named Head, External Affairs and Collaborations, and Peter Bream is Diadem's new Chief Financial Officer (CFO). They join Simona Piccirella, PhD, Vice President of Operations and DevelopmentĀ and Chief Executive Officer Paul Kinnon at Diadem.
- They join Simona Piccirella, PhD, Vice President of Operations and Developmentand Chief Executive Officer Paul Kinnon at Diadem.
- Simona has already played a major role in growing Diadem and developing the AlzoSure technology to this stage.
- Their contributions will be instrumental as we prepare for the commercialization of AlzoSure Predict in the new year."
- The company is also developing AlzoSure Confirm, a blood-based diagnostic test for AD that has shown promising results in early studies.